Crizotinib 250 MG

DRUG3 trials

Sponsors

National Cheng-Kung University Hospital, Hunan Province Tumor Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

ALK Gene MutationEGFR Gene MutationEndometrial Cancer RecurrentMET Gene MutationNon Small Cell Lung CancerROS1 Gene MutationRare Tumor

Phase 2

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

TerminatedNCT04030429

National Cheng-Kung University HospitalEndometrial Cancer Recurrent

Start: 2019-09-01End: 2025-06-01Updated: 2025-07-16

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

RecruitingNCT04322890

Hunan Province Tumor HospitalALK Gene Mutation, EGFR Gene Mutation, MET Gene Mutation +2

Start: 2020-04-16End: 2027-12-24Target: 6000Updated: 2024-10-22

PLATFORM Study of Precision Medicine for Rare Tumors

RecruitingNCT04423185

Cancer Institute and Hospital, Chinese Academy of Medical SciencesRare Tumor

Start: 2020-08-15End: 2028-07-01Target: 770Updated: 2025-02-11

Related Papers

Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours

BMJ Open2021-06-019 citations